Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

349 results about "Treatment dose" patented technology

Fluid component analysis system and method for glucose monitoring and control

ActiveUS20100121170A1Preventing hypoglycemiaDrug and medicationsMedical devicesAnalyteMedicine
Disclosed are methods and apparatuses for determining analyte concentration in a sample such as bodily fluid. Systems and methods disclosed herein can also include a treatment dosing system to infuse or inject a treatment dose (e.g. insulin, dextrose, etc.) and provide glycemic control. The dose of the treatment drug may be based on the patient's calculated sensitivity to treatment dosing, for example. The dose of the treatment drug may be based on the concentration of the analyte or the average value for the concentration of the analyte and / or the rate of change of the value of the concentration of the analyte. Delivery of the treatment drug can be cut off if the determined analyte concentration indicates that continued delivery would be harmful to the patient.
Owner:OPTISCAN BIOMEDICAL +1

Fluid component analysis system and method for glucose monitoring and control

Disclosed are methods and apparatus for determining analyte concentration in a sample such as bodily fluid. Systems and methods disclosed herein can also include a treatment dosing system to infuse or inject a treatment drug (e.g. insulin or glucose) and provide glycemic control. The dose of the treatment drug may be based on the concentration of the analyte or the average value for the concentration of the analyte and / or the rate of change of the value of the concentration of the analyte.
Owner:INSULET CORP +1

Therapy delivery system having an open architecture and a method thereof

A therapy delivery system having an open architecture and method of providing thereof are disclosed. The present invention provides a therapy dosage module having a control algorithm that can be replaced with a predefined or independently defined control algorithm. The tools necessary to create and test such control algorithms in the therapy dosage module in a simulated environment before implementing it in a live therapy system are also disclosed.
Owner:ROCHE DIABETES CARE INC

Orthovoltage radiotherapy

ActiveUS20080212738A1Dry up neovascular membraneStabilized and improved acuityHandling using diaphragms/collimetersRadiation beam directing meansRadiosurgeryBeam energy
A radiosurgery system is described that is configured to deliver a therapeutic dose of radiation to a target structure in a patient. In some embodiments, inflammatory ocular disorders are treated, specifically macular degeneration. In some embodiments, other disorders or tissues of a body are treated with the dose of radiation. In some embodiments, the target tissues are placed in a global coordinate system based on ocular imaging. In some embodiments, the target tissues inside the global coordinate system lead to direction of an automated positioning system that is directed based on the target tissues within the coordinate system. In some embodiments, a treatment plan is utilized in which beam energy and direction and duration of time for treatment is determined for a specific disease to be treated and / or structures to be avoided. In some embodiments, a fiducial marker is used to identify the location of the target tissues. In some embodiments, radiodynamic therapy is described in which radiosurgery is used in combination with other treatments and can be delivered concomitant with, prior to, or following other treatments.
Owner:CARL ZEISS MEDITEC INC

High efficient delivery of a large therapeutic mass aerosol

A method for delivering a therapeutic dose of a bioactive agent to the pulmonary system, in a single, breath-activated step, comprises administering from a receptacle enclosing a mass of particles, to a subject's respiratory tract, particles which have a tap density of less than 0.4 g / cm3 and deliver at least about 50% of the mass of particles. Another method of delivering a therapeutic dose of a bioactive agent to the pulmonary system, in a single breath, includes administering from a receptacle enclosing a mass of particles, to a subject's respiratory tract, particles which have a tap density of at least 0.4 g / cm3 and deliver at least about 10 milligrams of the bioactive agent. The receptacle can have a volume of at least 0.37 cm3.
Owner:CIVITAS THERAPEUTICS

Real-time, on-line and offline treatment dose tracking and feedback process for volumetric image guided adaptive radiotherapy

A method of treating an object with radiation that includes generating volumetric image data of an area of interest of an object and emitting a therapeutic radiation beam towards the area of interest of the object in accordance with a reference plan. The method further includes evaluating the volumetric image data and at least one parameter of the therapeutic radiation beam to provide a real-time, on-line or off-line evaluation and on-line or off-line modification of the reference plan.
Owner:WILLIAM BEAUMONT HOSPITAL

Stent device and method

A stent for delivering a therapeutic dose of the immnuosupressant tacrolimus is disclosed.
Owner:BOSTON SCI SCIMED INC

Computer assisted radiotherapy dosimeter system and a method therefor

In order to facilitate the display and evaluation of data acquired while irradiating a body, e.g. a patient undergoing radiation therapy, a dosimetry system has a plurality of sensors for disposition on, in or near the body to be irradiated and connected to a sensor reading instrument which is interfaced with a display system, for example a personal computer, which is arranged to display, in use, one or more representations, for example drawings or photographs, of the body to be irradiated, along with the positions and the dose data for those specific locations where the dosimeter sensors were placed.
Owner:BEST THERATRONICS +1

Methods for assisting recovery of damaged brain and spinal cord using arrays of X-ray microplanar beams

A method of assisting recovery of an injury site of brain or spinal cord injury includes providing a therapeutic dose of X-ray radiation to the injury site through an array of parallel microplanar beams. The dose at least temporarily removes regeneration inhibitors from the irradiated regions. Substantially unirradiated cells surviving between the microplanar beams migrate to the in-beam irradiated portion and assist in recovery. The dose may be administered in dose fractions over several sessions, separated in time, using angle-variable intersecting microbeam arrays (AVIMA). Additional doses may be administered by varying the orientation of the microplanar beams. The method may be enhanced by injecting stem cells into the injury site.
Owner:WASHINGTON UNIV IN SAINT LOUIS +1

Method and synergistic composition for treating attention deficit/hyperactivity disorder

A composition and method for treating Attention Deficit / Hyperactivity Disorder (ADHD) is provided which can be used both with and without ethical drugs now used to treat ADHD. The composition contains dimethylaminoethanol (DMAE), omega 3-fatty acids, betaine, oligomeric proanthocyanidins (OPC), folic acid, vitamins C, E, B12, B6, B5 and beta-carotene and minerals (calcium, magnesium, zinc and selenium). Ethical drugs such as amphetamines, methylphenidate HCl and pemoline are known to control ADHD, but each has significant side effects when used in their therapeutic dose. When combining the composition with such ethical drugs, the amount of the ethical drug can be lowered below a level which causes undesirable side effects which is an important feature. Preferred compositions contain one or more of lecithin, choline, 5-hydroxytryptophan, tyrosine, Reishi Extract, Kava Extract, Gingko, Ginseng and St. John's Wort.
Owner:PHILIP C LANG

General purpose, high accuracy dosimeter reader

A general purpose high accuracy dosimeter reader, 80, for determination of a treatment condition, based on comparison of an image of treated dosimeter, 111, with a series of images of pre-treated dosimeter, 114, is disclosed. A dosimeter undergoes noticeable changes, such as a color change upon treatment with certain materials, such as toxic gases and processes, such as ionizing radiation and sterilization is pre-treated. The dosimeter is imaged with an imaging device, 115, such as charge-coupled device camera and images of the dosimeter or the changes, e.g., color change, are stored in an information storage device, 118. In order to determine the treatment condition, the treatment dosimeter is imaged and the image is compared with the series of pre-treated images of the dosimeter using software. The closest match of the treated dosimeter with the pre-treated and pre-imaged dosimeter would indicate the treatment conditions. The process and device can be used for almost any indicating device, process and treatment.
Owner:JP LAB INC +1

Inhibition of AXL Signaling in Anti-Metastatic Therapy

Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL and its ligand GAS6.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV

Highly efficient delivery of a large therapeutic mass aerosol

A method for delivering a therapeutic dose of a bioactive agent to the pulmonary system, in a single, breath-activated step, comprises administering from a receptacle enclosing a mass of particles, to a subject's respiratory tract, particles which have a tap density of less than 0.4 g / cm3 and deliver at least about 50% of the mass of particles. Another method of delivering a therapeutic dose of a bioactive agent to the pulmonary system, in a single breath, includes administering from a receptacle enclosing a mass of particles, to a subject's respiratory tract, particles which have a tap density of at least 0.4 g / cm3 and deliver at least about 10 milligrams of the bioactive agent. The receptacle can have a volume of at least 0.37 cm3.
Owner:CIVITAS THERAPEUTICS

Patient-specific dosimetry

A patient-specific optimally effective radiation dose for administration of a radiopharmaceutical to a patient for treatment of a disease may be established by basing the calculation of the appropriate therapeutic dose on factors such as the desired total body dose, the maximum tolerated dose, the typical clearance profile of the radiopharmaceutical, the patient's mass or maximum effective mass, and the patient-specific residence time of the radiopharmaceutical or an analog in the whole body of the patient. The use of the method allows for treatment of a patient with an appropriate dose which is maximally effective against the disease yet minimally toxic. The determination of a patient-specific therapeutic dose may be assisted by the use of a software program set to the particular parameters of the radiopharmaceutical.
Owner:GLAXO SMITHKLINE LLC +1

Device and method for treatment of dermatomycosis, and in particular onychomycosis

A device is provided that allows for target treatment of infections, caused by dermatophytes, yeast fungus, and mould fungus, such as onychomycosis and dermatophytosis. The device comprises a nitric oxide (NO) eluting polymer arranged to contact the infected area, such that a therapeutic dose of nitric oxide is eluted from said nitric oxide eluting polymer to said area. The nitric oxide (NO) eluting polymer is integrated with a carrier material, such that said carrier material, in use, regulates and controls the elution of said therapeutic dosage of nitric oxide (NO). Furthermore, a corresponding manufacturing method is provided.
Owner:NOLABS AB

Device and method for delivery of two or more drug agents

ActiveCN102740907AEasy dose settingEase of dosingAmpoule syringesAutomatic syringesDose profileMechanical drive
A computerized electro-mechanical drug delivery device (10) configured to deliver at least one dose of two or more medicaments. The device comprises a control unit (300). An electro-mechanical drive unit (500, 600) is operably coupled to the control unit and a primary reservoir (90) for a first medicament and a secondary reservoir (100) for a fluid agent, e.g. a second medicament. An operator interface (60) is in communication with the control unit (300). A single dispense assembly (200) is configured for fluid communication with the primary (90) and the secondary (100) reservoir. Activation of the operator panel sets a first dose from the primary reservoir and based on the first dose and a therapeutic dose profile (860), the control unit (300) is configured to determine a dose or range of the fluid agent. Alternatively, the control unit determines or calculates a dose or range of a third medicament.
Owner:SANOFI AVENTIS DEUT GMBH

Non-voxel-based broad-beam (NVBB) algorithm for intensity modulated radiation therapy dose calculation and plan optimization

ActiveUS20110122997A1Increase optimization processing timeImprove accuracyX-ray/gamma-ray/particle-irradiation therapyVoxelDose profile
A method of calculating a dose distribution for a patient for use in a radiation therapy treatment plan. The method includes acquiring an image of a volume within the patient, defining a radiation source, and defining a reference plane oriented between the radiation source and the patient. The method also includes generating a radiation therapy treatment plan, wherein the plan includes a plurality of rays that extend between the radiation source and the patient volume, and calculating a three-dimensional dose volume for the patient volume from the plurality of rays that intersect the reference plane without first having to independently calculate a dose distribution on each of the plurality of rays. The method can also include displaying the three-dimensional dose volume.
Owner:TOMOTHERAPY INC

Algae supplement and treatment method

InactiveUS20080124286A1Enhances epidermal stem cell productionExtend the life cycleCosmetic preparationsBiocidePhylum CyanobacteriaCuticle
This invention relates to a method and composition for enhancing epidermal and / or hair follicle stem cell production, cell renewal, and / or growth of the skin, hair and nails, by topical administration of a therapeutic dosage of cyanobacteria and green algae and / or both simultaneous enteral and topical administration of a therapeutic dosage of cyanobacteria and green algae.
Owner:LISSON JEROLD B

Cross-linked high amylose starch resistant to amylase as a matrix for the slow release of biologically active compounds

The present invention is concerned with a solid slow release oral pharmaceutical dosage unit resistant to amylase which comprises a solid dosage unit made up of an admixture of a therapeutic dosage of an orally effective pharmaceutical product, an optional polysaccharide or polyol, and cross-linked high amylose starch, wherein the cross-linking of the high amylose starch has been carried out with a covalent or non-covalent cross-linking agent with from about 0.1 g to about 30 g of cross-linking agent per 100 g of high amylose starch.
Owner:LABOPHARM INC

Benchmark system for radiation therapy planning

A system for evaluating radiation treatment planning generates a fictitious treatment dose matrix with a quality of dose placement beyond that achievable with physically realizable radiation therapy machines. Such a fictitious treatment dose matrix provides an objective measure that is readily tailored to different clinical situations, and although unattainable, thereby provides a benchmark allowing evaluation of radiation plan goals and the radiation plans between different multiple clinical situations and individuals.
Owner:SUN NUCLEAR

Specific Anti-cd38 antibodies for treating human cancers

The present disclosure concerns an antibody that specifically binds CD38 which is capable of killing a CD38+ cell by induction of apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and complement-dependent cytotoxicity. The disclosed antibody may be used as a medicament or in the making of a medicament, wherein the antibody is to be administered to a human subject in a safe therapeutic dose of about 20 mg / kg or below. In one embodiment, the medicament is for treating CD38+ multiple Myeloma in humans.
Owner:SANOFI SA

Methods and kits for diagnosis of cancer and prediction of therapeutic value

A method for identifying a patient for cancer therapy can include administering a diagnostic dose of a detectably labeled first binding agent to a patient, the detectably labeled binding agent being capable of binding a molecular target. The method also includes selecting a patient for administration of a therapeutic dose of a second binding agent capable of binding a cellular target, wherein the selected patient exhibits a positive reading for the detectably labeled first binding agent. Furthermore, the method can include administering a therapeutic dose of the second binding agent to the patient.
Owner:CORNELL UNIVERSITY

Device for treatment of disorders in the oral cavity with nitric oxide, and manufacturing process for the same

A device and method for therapeutical treatment of disorders in the oral cavity and a process for manufacturing of said device is disclosed. The device comprises a nitric oxide (NO) eluting polymer. The nitric oxide (NO) eluting polymer is configured to elute a therapeutic dosage of nitric oxide (NO) when used in the oral cavity. The device allows for target treatment of infections or wounds in the oral cavity. The device comprising the nitric oxide (NO) eluting polymer is arranged to contact an infected area in the oral cavity, such that a therapeutic dose of nitric oxide is eluted from said nitric oxide eluting polymer to said area. The nitric oxide (NO) eluting polymer is integrated with a carrier material, such that said carrier material, in use, regulates and controls the elution of said therapeutic dosage of nitric oxide (NO).
Owner:NOLABS AB

System and method for determining a treatment dose for a patient

In certain embodiments, a method of maintaining health of a patient uses an analyte detection system. The analyte detection system is coupled to the patient such that a bodily fluid of the patient is accessible to the analyte detection system. The method includes automatically initiating and conducting a measurement of an analyte in the bodily fluid using the analyte detection system. The method further includes determining a treatment dose for the patient based on the measurement using the analyte detection system.
Owner:OPTISCAN BIOMEDICAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products